Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3229933rdf:typepubmed:Citationlld:pubmed
pubmed-article:3229933lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:3229933lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3229933lifeskim:mentionsumls-concept:C0005682lld:lifeskim
pubmed-article:3229933lifeskim:mentionsumls-concept:C0205276lld:lifeskim
pubmed-article:3229933lifeskim:mentionsumls-concept:C0814337lld:lifeskim
pubmed-article:3229933lifeskim:mentionsumls-concept:C0205124lld:lifeskim
pubmed-article:3229933lifeskim:mentionsumls-concept:C0085752lld:lifeskim
pubmed-article:3229933pubmed:issue6lld:pubmed
pubmed-article:3229933pubmed:dateCreated1989-4-13lld:pubmed
pubmed-article:3229933pubmed:abstractTextForty-nine patients with superficial Ta-Tl, G1-G2 vesical tumours were subjected to local Adriamycin treatment. Following transurethral resection (TUR), 50 mg doses of Adriamycin in 50 ml physiological salt solution were instilled into the bladder 4 times at intervals of one week and then 12 times at intervals of one month (i.e. a total of 15 times). Upon exclusion of two patients who failed to appear at follow-ups and one more in whom treatment was discontinued because of side effects, the remaining 46 were followed up cystoscopically for 2 years at intervals of 3 months. The recurrence rates of 12% and 24% for the primary and secondary tumours, respectively, were found to be significantly lower than those found in the control group (37% and 65%).lld:pubmed
pubmed-article:3229933pubmed:languageenglld:pubmed
pubmed-article:3229933pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3229933pubmed:citationSubsetIMlld:pubmed
pubmed-article:3229933pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3229933pubmed:statusMEDLINElld:pubmed
pubmed-article:3229933pubmed:issn0301-1623lld:pubmed
pubmed-article:3229933pubmed:authorpubmed-author:KondásJJlld:pubmed
pubmed-article:3229933pubmed:authorpubmed-author:SzentgyörgyiE...lld:pubmed
pubmed-article:3229933pubmed:authorpubmed-author:SzökeDDlld:pubmed
pubmed-article:3229933pubmed:issnTypePrintlld:pubmed
pubmed-article:3229933pubmed:volume20lld:pubmed
pubmed-article:3229933pubmed:ownerNLMlld:pubmed
pubmed-article:3229933pubmed:authorsCompleteYlld:pubmed
pubmed-article:3229933pubmed:pagination611-5lld:pubmed
pubmed-article:3229933pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:meshHeadingpubmed-meshheading:3229933-...lld:pubmed
pubmed-article:3229933pubmed:year1988lld:pubmed
pubmed-article:3229933pubmed:articleTitleLocal adriamycin treatment for prevention of recurrence of superficial bladder tumours.lld:pubmed
pubmed-article:3229933pubmed:affiliationDepartment of Urologic Surgery, Municipal Péterfy Sándor Street Hospital and Outpatient Clinic, Budapest, Hungary.lld:pubmed
pubmed-article:3229933pubmed:publicationTypeJournal Articlelld:pubmed